EP2100614B8 - Antibody against PDGFR-alpha for use in the treatment of tumours - Google Patents

Antibody against PDGFR-alpha for use in the treatment of tumours Download PDF

Info

Publication number
EP2100614B8
EP2100614B8 EP09075103.3A EP09075103A EP2100614B8 EP 2100614 B8 EP2100614 B8 EP 2100614B8 EP 09075103 A EP09075103 A EP 09075103A EP 2100614 B8 EP2100614 B8 EP 2100614B8
Authority
EP
European Patent Office
Prior art keywords
tumours
alpha
treatment
antibody against
pdgfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP09075103.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2100614B1 (en
EP2100614A3 (en
EP2100614A2 (en
Inventor
Nick Loizos
Jim Huber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone LLC filed Critical ImClone LLC
Priority to EP12162951A priority Critical patent/EP2505205A1/en
Priority to SI200631722T priority patent/SI2100614T1/sl
Priority to PL09075103T priority patent/PL2100614T3/pl
Publication of EP2100614A2 publication Critical patent/EP2100614A2/en
Publication of EP2100614A3 publication Critical patent/EP2100614A3/en
Publication of EP2100614B1 publication Critical patent/EP2100614B1/en
Priority to CY20131101013T priority patent/CY1114603T1/el
Application granted granted Critical
Publication of EP2100614B8 publication Critical patent/EP2100614B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP09075103.3A 2005-06-17 2006-06-19 Antibody against PDGFR-alpha for use in the treatment of tumours Active EP2100614B8 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP12162951A EP2505205A1 (en) 2005-06-17 2006-06-19 Anti-PDGFR Alpha Antibodies
SI200631722T SI2100614T1 (sl) 2005-06-17 2006-06-19 PROTITELO PROTI PDGFR-alfa ZA UPORABO PRI ZDRAVLJENJU TUMORJEV
PL09075103T PL2100614T3 (pl) 2005-06-17 2006-06-19 Przeciwciała przeciwko PDGFR alfa do zastosowania w leczeniu guzów nowotworowych
CY20131101013T CY1114603T1 (el) 2005-06-17 2013-11-14 ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69192005P 2005-06-17 2005-06-17
EP06785127A EP1909819A4 (en) 2005-06-17 2006-06-19 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF METASTATIC BONE CANCER

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP06785127A Division EP1909819A4 (en) 2005-06-17 2006-06-19 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF METASTATIC BONE CANCER
EP06785127.9 Division 2006-06-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP12162951A Division EP2505205A1 (en) 2005-06-17 2006-06-19 Anti-PDGFR Alpha Antibodies
EP12162951.3 Division-Into 2012-04-03

Publications (4)

Publication Number Publication Date
EP2100614A2 EP2100614A2 (en) 2009-09-16
EP2100614A3 EP2100614A3 (en) 2010-02-17
EP2100614B1 EP2100614B1 (en) 2013-10-09
EP2100614B8 true EP2100614B8 (en) 2013-11-20

Family

ID=37571297

Family Applications (4)

Application Number Title Priority Date Filing Date
EP09075103.3A Active EP2100614B8 (en) 2005-06-17 2006-06-19 Antibody against PDGFR-alpha for use in the treatment of tumours
EP06785127A Withdrawn EP1909819A4 (en) 2005-06-17 2006-06-19 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF METASTATIC BONE CANCER
EP09075102.5A Not-in-force EP2100618B1 (en) 2005-06-17 2006-06-19 An anti-PDGFRalpha antibody for use in the treatment of metastatic bone cancer
EP12162951A Withdrawn EP2505205A1 (en) 2005-06-17 2006-06-19 Anti-PDGFR Alpha Antibodies

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP06785127A Withdrawn EP1909819A4 (en) 2005-06-17 2006-06-19 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF METASTATIC BONE CANCER
EP09075102.5A Not-in-force EP2100618B1 (en) 2005-06-17 2006-06-19 An anti-PDGFRalpha antibody for use in the treatment of metastatic bone cancer
EP12162951A Withdrawn EP2505205A1 (en) 2005-06-17 2006-06-19 Anti-PDGFR Alpha Antibodies

Country Status (21)

Country Link
US (3) US8128929B2 (Direct)
EP (4) EP2100614B8 (Direct)
JP (4) JP2009501141A (Direct)
KR (3) KR101246504B1 (Direct)
CN (3) CN101612399B (Direct)
BE (1) BE2017C007I2 (Direct)
BR (2) BRPI0622073A8 (Direct)
CA (3) CA2612449A1 (Direct)
CY (3) CY1114603T1 (Direct)
DK (2) DK2100618T3 (Direct)
ES (2) ES2435727T3 (Direct)
HU (1) HUS1700015I1 (Direct)
IL (3) IL188151A0 (Direct)
LT (1) LTC2100614I2 (Direct)
LU (1) LUC00012I2 (Direct)
NL (1) NL300869I2 (Direct)
PL (2) PL2100618T3 (Direct)
PT (2) PT2100614E (Direct)
RU (3) RU2008101772A (Direct)
SI (2) SI2100614T1 (Direct)
WO (1) WO2006138729A2 (Direct)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2100618T3 (pl) * 2005-06-17 2014-07-31 Imclone Llc Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
WO2007092453A2 (en) * 2006-02-03 2007-08-16 Imclone Systems Incorporated Igf-ir antagonists as adjuvants for treatment of prostate cancer
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
WO2009021150A2 (en) 2007-08-08 2009-02-12 California Pacific Medical Center Platelet derived growth factor receptor supports cytomegalovirus infectivity
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
US20090280112A1 (en) * 2008-05-05 2009-11-12 The Regents Of The University Of California Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
PL2575935T5 (pl) 2010-06-07 2023-12-11 Amgen Inc. Urządzenie do podawania leku
JP2013177317A (ja) * 2010-06-24 2013-09-09 Meneki Seibutsu Kenkyusho:Kk 抗ｐｄｇｆ受容体抗体
CN103108658B (zh) * 2010-07-02 2015-08-19 米迪缪尼有限公司 抗体制剂
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
SI2699293T1 (sl) 2011-04-20 2019-05-31 Amgen Inc. Avtoinjekcijski aparat
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
DK3045189T3 (en) 2011-10-14 2018-06-18 Amgen Inc Injector and mounting method
CA2852127C (en) 2011-11-11 2020-10-27 Duke University Combination drug therapy for the treatment of solid tumors
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
ES2860954T3 (es) 2012-11-21 2021-10-05 Amgen Inc Dispositivo de administración de fármacos
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
WO2014138449A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
KR102295834B1 (ko) 2013-03-15 2021-08-30 암젠 인크 인체 윤곽 적응성을 가진 자기 주사기 장치
EP2968760B1 (en) 2013-03-15 2024-01-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
CA2897825C (en) 2013-03-22 2022-05-24 Scott R. Gibson Injector and method of assembly
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
AU2014340171B2 (en) 2013-10-24 2019-05-30 Amgen Inc. Injector and method of assembly
CA3168888A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
WO2015095587A1 (en) * 2013-12-20 2015-06-25 Boston Scientific Scimed, Inc. Integrated catheter system
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
WO2015171777A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
KR102416904B1 (ko) 2014-06-03 2022-07-04 암겐 인코포레이티드 약물 전달 디바이스에 의해 수집된 데이터를 원격으로 프로세싱하기 위한 시스템들 및 방법들
JP6480479B2 (ja) * 2014-07-03 2019-03-13 イムクローン リミテッド ライアビリティ カンパニー Ｇｉｓｔの治療法
EA201692564A1 (ru) * 2014-07-03 2017-09-29 Имклон Ллк Комбинированная терапия
US10695506B2 (en) 2014-10-14 2020-06-30 Amgen Inc. Drug injection device with visual and audio indicators
KR20170075778A (ko) 2014-10-27 2017-07-03 에이전시 포 사이언스, 테크놀로지 앤드 리서치 항-tim-3 항체
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
AU2016220141B2 (en) 2015-02-17 2018-07-12 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
MY200764A (en) 2015-12-16 2024-01-14 Regeneron Pharma Compositions and methods of manufacturing protein microparticles
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124B1 (en) 2016-06-03 2026-02-11 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
MA45493A (fr) * 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US10711066B2 (en) 2016-07-28 2020-07-14 Elanco Us Inc. Anti-canine platelet derived growth factor receptor alpha antibody
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
JP6908709B2 (ja) 2017-01-06 2021-07-28 エービーエル バイオ インコーポレイテッド 抗α−ｓｙｎ抗体およびその使用
US20190358411A1 (en) 2017-01-17 2019-11-28 Amgen Inc. Injection devices and related methods of use and assembly
JP7280189B2 (ja) 2017-02-17 2023-05-23 アムジエン・インコーポレーテツド 薬物送達装置用の挿入機構
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
IL268478B2 (en) 2017-03-07 2023-10-01 Amgen Inc Inserting a needle using super pressure
AU2018230486B2 (en) 2017-03-09 2023-05-11 Amgen Inc. Insertion mechanism for drug delivery device
WO2018169779A1 (en) 2017-03-17 2018-09-20 ImClone, LLC Combination therapy for pancreatic cancer
KR20240042212A (ko) 2017-03-28 2024-04-01 암겐 인코포레이티드 플런저 로드 및 주사기 조립 시스템 및 방법
EP3634539A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CN110709121B (zh) 2017-06-08 2022-06-24 安进公司 扭矩驱动式药物递送装置
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
US11395880B2 (en) 2017-06-23 2022-07-26 Amgen Inc. Electronic drug delivery device
ES2972207T3 (es) 2017-07-14 2024-06-11 Amgen Inc Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
EP4292576A3 (en) 2017-07-21 2024-01-17 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070497A1 (en) 2017-10-04 2019-04-11 Imclone Llc POLY THERAPY AGAINST CANCER
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
US11813426B2 (en) 2017-10-06 2023-11-14 Amgen Inc. Drug delivery device including seal member for needle of syringe
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
US11305026B2 (en) 2017-11-03 2022-04-19 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
ES2994389T3 (en) 2017-11-06 2025-01-23 Amgen Inc Drug delivery device with placement and flow sensing
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
CA3079665A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
CA3079540A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
EP3710089A1 (en) 2017-11-16 2020-09-23 Amgen Inc. Autoinjector with stall and end point detection
EP4403218A3 (en) 2017-12-14 2024-11-06 ABL Bio, Inc. Bispecific antibody to a-syn/igf1r and use thereof
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
WO2019231803A1 (en) 2018-05-31 2019-12-05 Imclone Llc Combination therapy for soft tissue sarcoma
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CN112469454B (zh) 2018-07-24 2024-01-26 安进公司 用于施用药物的输送装置
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
CN112351804A (zh) 2018-07-24 2021-02-09 安进公司 用于施用药物的输送装置
US12109389B2 (en) 2018-07-31 2024-10-08 Amgen Inc. Fluid path assembly for a drug delivery device
AU2019347710B2 (en) 2018-09-24 2025-05-08 Amgen Inc. Interventional dosing systems and methods
AU2019350660B2 (en) 2018-09-28 2024-09-26 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
EP3860685A1 (en) 2018-10-02 2021-08-11 Amgen Inc. Injection systems for drug delivery with internal force transmission
AR116607A1 (es) 2018-10-05 2021-05-26 Amgen Inc Dispositivo de administración de fármacos con indicador de dosis
EP3866889A1 (en) 2018-10-15 2021-08-25 Amgen Inc. Platform assembly process for drug delivery device
MX2021004219A (es) 2018-10-15 2021-05-27 Amgen Inc Dispositivo de administracion de farmacos con mecanismo de amortiguacion.
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
US12485219B2 (en) 2018-11-01 2025-12-02 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US11279698B2 (en) 2018-11-20 2022-03-22 Cornell University Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
CN109134655B (zh) * 2018-11-28 2019-02-26 上海复宏汉霖生物技术股份有限公司 一种抗PDGFRα的单克隆抗体及其制备方法和应用
AU2020263289B2 (en) 2019-04-24 2025-05-22 Amgen Inc. Syringe sterilization verification assemblies and methods
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC Compositions and methods for the prevention and treatment of hearing loss
WO2022197929A1 (en) * 2021-03-19 2022-09-22 Eli Lilly And Company Methods of treating cancer with pdgfr alpha inhibitors
CN117320964A (zh) 2021-05-21 2023-12-29 美国安进公司 优化药物容器的灌装方案的方法
EP4430047A1 (en) 2021-11-08 2024-09-18 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2024207070A1 (en) * 2023-04-04 2024-10-10 Telix Pharmaceuticals (Innovations) Pty Ltd Methods of treating cancers expressing pdgfralpha
WO2024207046A1 (en) * 2023-04-04 2024-10-10 Telix Pharmaceuticals (Innovations) Pty Ltd Reagents and methods for imaging cancers expressing pdgfralpha
WO2024207069A1 (en) * 2023-04-04 2024-10-10 Telix Pharmaceuticals (Innovations) Pty Ltd Reagents and methods for imaging cancers expressing pdgfralpha
AU2023439766A1 (en) * 2023-04-04 2025-09-11 Eli Lilly And Company Methods of treating cancers expressing pdgfralpha
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4774321A (en) 1986-12-01 1988-09-27 Massachusetts Institute Of Technology DP100 EGF and insulin-binding protein from Drosophila cells
EP0308500B1 (en) 1987-04-06 1993-06-16 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
US5200509A (en) 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ATE119198T1 (de) 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US6228600B1 (en) 1992-07-20 2001-05-08 The United States Of America As Represented By The Department Of Health And Human Services Immunoassays for the alpha platelet-derived growth factor receptor
DK0456766T3 (da) 1989-02-09 1999-11-08 Us Health Gen for receptor for type alfa-blodplade-afledt vækstfaktor
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US7252929B2 (en) 1989-02-09 2007-08-07 United States Of America, As Represented By The Secretary, Dept Of Health & Human Services Methods for identifying alpha PDGFR agonists and antagonists
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
WO1991016051A1 (en) 1990-04-16 1991-10-31 Rhône-Poulenc Rorer International (Holdings) Inc. Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
JPH06503711A (ja) 1990-08-28 1994-04-28 カイロン　コーポレイション 新規インシュリン様成長因子結合タンパク質（ｉｇｆｂｐ―４）
WO1992013867A1 (en) 1991-01-31 1992-08-20 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5262308A (en) 1992-01-28 1993-11-16 Thomas Jefferson University Cell lines which constitutively express IGF-1 and IGF-1 R
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5597563A (en) 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
EP0686044B1 (en) 1993-02-25 1998-09-02 ZymoGenetics, Inc. Inhibition of intimal hyperplasia using antibodies to pdgf receptors
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5976534A (en) 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
JPH08508409A (ja) 1993-04-06 1996-09-10 シーダーズ − サイナイ メディカル センター 変異インスリン様増殖因子▲ｉ▼受容体サブユニットおよびそれらの使用方法
JPH09507578A (ja) 1994-01-14 1997-07-29 ジェネンテク，インコーポレイテッド インスリン受容体チロシンキナーゼインヒビターに対するアンタゴニスト
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
EP1018518A2 (en) 1994-06-24 2000-07-12 Vladimir P. Torchilin Use of autoantibodies for tumor therapy and prophylaxis
US5939269A (en) 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1997018241A1 (en) 1995-11-14 1997-05-22 Thomas Jefferson University Inducing resistance to tumor growth with soluble igf-1 receptor
ATE217873T1 (de) 1996-01-23 2002-06-15 Novartis Erfind Verwalt Gmbh Pyrrolopyrimidinen und verfahren zu deren herstellung
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AUPN999096A0 (en) 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
JP2000512990A (ja) 1996-06-24 2000-10-03 ファイザー・インク 過増殖性疾患を処置するためのフェニルアミノ置換三環式誘導体
US5798266A (en) 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US6071891A (en) 1996-11-22 2000-06-06 Regents Of The University Of Minnesota Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
EP1080113A4 (en) 1998-05-15 2002-04-17 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
ES2211175T3 (es) 1998-09-29 2004-07-01 Wyeth Holdings Corporation Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.
CZ20011049A3 (cs) 1998-10-05 2002-08-14 Pharmexa A/S Imunogenní kompozice a způsob selekce imunogenního analogu
AU763626B2 (en) 1998-11-19 2003-07-31 Warner-Lambert Company N-(4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl- propoxy)-quinazolin-6-yl)-acrylamide, an irreversible inhibitor of tyrosine kinases
EP1006184A1 (en) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
HK1048430B (zh) 1999-07-27 2006-04-21 迈克尔‧米拉维特‧索里贝斯 一种非侵害性校正人类外耳形状的装置
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
RU2183461C2 (ru) * 2000-05-29 2002-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения сарком мягких тканей
US7329745B2 (en) 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
AU2001274536A1 (en) 2000-06-15 2002-01-02 Kyowa Hakko Kogyo Co. Ltd. Insulin-like growth factor-binding protein
US8153121B2 (en) 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
EA012079B3 (ru) 2001-01-05 2018-07-31 Пфайзер Инк. Моноклональное антитело к рецептору инсулиноподобного фактора роста i (igf-i) и способы его применения
US7071300B2 (en) 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
WO2002087618A1 (en) 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
WO2003059951A2 (fr) 2002-01-18 2003-07-24 Pierre Fabre Medicament Anticorps anti-igf-ir et leurs applications
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
EP1487856B1 (en) 2002-03-04 2010-07-28 Imclone LLC Human antibodies specific to kdr and uses thereof
CA2484000A1 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
JP5138867B2 (ja) 2002-08-01 2013-02-06 イミューノメディクス、インコーポレイテッド α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
PL378812A1 (pl) 2003-02-13 2006-05-29 Pfizer Products Inc. Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I
JP2007528201A (ja) 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
EP1613658B1 (en) 2003-04-02 2012-03-14 F. Hoffmann-La Roche AG Antibodies against insulin-like growth factor i receptor and uses thereof
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
RU2241452C1 (ru) * 2003-06-11 2004-12-10 Московский областной научно-исследовательский клинический институт Способ лечения метастазов в кости
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
AU2004263538B2 (en) 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
EP1656391B1 (en) * 2003-08-13 2010-10-13 Pfizer Products Inc. Modified human igf-1r antibodies
US20060263362A1 (en) * 2003-08-21 2006-11-23 Atsushi Ochiai Cancer metastasis inhibitor
EP1671647A1 (en) 2003-09-24 2006-06-21 Kyowa Hakko Kogyo Co., Ltd. Medicament for treating cancer
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
WO2005082415A2 (en) 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
AU2005222384A1 (en) * 2004-03-05 2005-09-22 Vegenics Limited Growth factor binding constructs materials and methods
JP4493485B2 (ja) 2004-04-28 2010-06-30 シャープ株式会社 太陽電池モジュール用配線部材、それを用いた太陽電池モジュールおよび太陽電池モジュール用配線部材の製造方法
WO2006008639A1 (en) 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2006020258A2 (en) 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
ES2356830T3 (es) 2004-12-03 2011-04-13 Schering Corporation Biomarcadores para preselección de pacientes para terapia de anti-igf-1r.
US20060134172A1 (en) 2004-12-21 2006-06-22 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1868649A4 (en) 2005-04-15 2011-06-29 Immunogen Inc ELIMINATION OF A POPULATION OF HETEROGENEOUS OR MIXED CELLS IN TUMORS
PL2100618T3 (pl) * 2005-06-17 2014-07-31 Imclone Llc Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
US20070009970A1 (en) 2005-07-08 2007-01-11 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
TWI478940B (zh) 2005-08-26 2015-04-01 Roche Glycart Ag 具有經改變細胞傳訊活性之改質抗原結合分子
PL1979001T3 (pl) 2005-12-13 2012-09-28 Medimmune Ltd Białka wiążące specyficzne dla insulinopodobnych czynników wzrostu i ich zastosowania
WO2010000008A1 (en) 2008-06-30 2010-01-07 Desi Raymond Richardson Thiosemicarbazone compounds and use thereof
DK200900548A (en) 2008-07-18 2010-01-19 Univ Koebenhavn Processes for manufacture of products from plants
MX2010013190A (es) 2008-07-18 2010-12-20 Hoffmann La Roche Fenilimidazopirazinas novedosas.

Also Published As

Publication number Publication date
BRPI0622074A8 (pt) 2017-10-10
IL198870A (en) 2013-03-24
EP2100618A3 (en) 2010-06-09
US8425911B2 (en) 2013-04-23
IL198869A0 (en) 2010-02-17
SI2100618T1 (sl) 2014-03-31
EP1909819A2 (en) 2008-04-16
LUC00012I1 (Direct) 2017-04-06
DK2100614T3 (da) 2013-10-28
CA2678008A1 (en) 2006-12-28
CN101612399B (zh) 2013-11-27
PL2100614T3 (pl) 2014-02-28
CY1115076T1 (el) 2016-12-14
LTC2100614I2 (lt) 2018-03-26
WO2006138729A2 (en) 2006-12-28
US20120034244A1 (en) 2012-02-09
RU2455026C2 (ru) 2012-07-10
KR20090027773A (ko) 2009-03-17
RU2502523C2 (ru) 2013-12-27
DK2100618T3 (en) 2014-03-03
EP2100618B1 (en) 2014-02-12
KR101246428B1 (ko) 2013-03-21
CY1114603T1 (el) 2016-10-05
LTPA2017011I1 (lt) 2017-05-10
BRPI0622073A8 (pt) 2017-10-03
CA2680945A1 (en) 2006-12-28
RU2009115363A (ru) 2010-10-27
EP2100614B1 (en) 2013-10-09
PT2100614E (pt) 2013-12-16
CN101612399A (zh) 2009-12-30
CN101613409B (zh) 2014-06-04
IL198870A0 (en) 2010-02-17
ES2452115T3 (es) 2014-03-31
BRPI0622074A2 (pt) 2011-07-19
KR20080047529A (ko) 2008-05-29
CA2680945C (en) 2014-03-18
BRPI0622073A2 (pt) 2011-07-19
CY2017013I1 (el) 2017-07-12
PL2100618T3 (pl) 2014-07-31
NL300869I2 (nl) 2017-05-24
EP1909819A4 (en) 2010-02-17
JP2009102444A (ja) 2009-05-14
EP2100614A3 (en) 2010-02-17
CA2678008C (en) 2013-07-30
US20090110678A1 (en) 2009-04-30
IL188151A0 (en) 2008-03-20
KR20090027774A (ko) 2009-03-17
PT2100618E (pt) 2014-04-07
WO2006138729A3 (en) 2009-02-12
JP5436883B2 (ja) 2014-03-05
SI2100614T1 (sl) 2014-03-31
CN101500597A (zh) 2009-08-05
BE2017C007I2 (Direct) 2026-02-02
EP2505205A1 (en) 2012-10-03
KR101246504B1 (ko) 2013-03-26
RU2455026C3 (ru) 2020-04-08
RU2009115364A (ru) 2010-10-27
CY2017013I2 (el) 2017-07-12
CN101613409A (zh) 2009-12-30
JP2009106306A (ja) 2009-05-21
BRPI0611984A2 (pt) 2009-07-07
JP5154470B2 (ja) 2013-02-27
US8128929B2 (en) 2012-03-06
EP2100614A2 (en) 2009-09-16
RU2008101772A (ru) 2009-07-27
US20120027767A1 (en) 2012-02-02
JP2012179060A (ja) 2012-09-20
JP2009501141A (ja) 2009-01-15
HK1135917A1 (en) 2010-06-18
IL198869A (en) 2011-09-27
US8574578B2 (en) 2013-11-05
CA2612449A1 (en) 2006-12-28
HUS1700015I1 (hu) 2017-07-28
EP2100618A2 (en) 2009-09-16
ES2435727T3 (es) 2013-12-23
LUC00012I2 (Direct) 2017-06-19

Similar Documents

Publication Publication Date Title
EP2100614B8 (en) Antibody against PDGFR-alpha for use in the treatment of tumours
WO2004030625A3 (en) Synergistic methods and compositions for treating cancer
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
ATE526987T1 (de) Dr5-antikörper und deren verwendung
GB0504988D0 (en) Device and method for the treatment of diseased tissue such as tumors
TW200515910A (en) Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibitor of cancer
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2009036188A3 (en) Insulin-like growth factor binding protein 7 for treatment of cancer
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
TW200716141A (en) Compositions and methods for treatment for neoplasms
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2009025806A3 (en) Use of vegfr-2 inhibitors for treating metastatic cancer
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
WO2009067397A3 (en) Treatment for solid tumors
WO2008155533A3 (en) Phenothiazine compounds for treating mild cognitive impairment
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
WO2007079202A3 (en) Treatment for acute lymhoblastic leukemia
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2007079146A8 (en) Treatment for non-hodgkin's lymphoma
EP2716285A3 (en) New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
WO2008036254A3 (en) Autophagic compounds and tyrosine kinase inhibitors for treating cancer
GB2460976B (en) Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1909819

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HUBER, JIM

Inventor name: LOIZOS, NICK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DREXEL UNIVERSITY COLLEGE OF MEDICINE

Owner name: UNIVERSITY OF WASHINGTON

Owner name: IMCLONE LLC

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DREXEL UNIVERSITY COLLEGE OF MEDICINE

Owner name: UNIVERSITY OF WASHINGTON

Owner name: IMCLONE LLC

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135917

Country of ref document: HK

17P Request for examination filed

Effective date: 20100527

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHILADELPHIA HEALTH AND EDUCATION CORPORATION D/B/

Owner name: UNIVERSITY OF WASHINGTON

Owner name: IMCLONE LLC

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20110215

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHILADELPHIA HEALTH AND EDUCATION CORPORATION D/B/

Owner name: IMCLONE LLC

Owner name: UNIVERSITY OF WASHINGTON

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130418

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1909819

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 635268

Country of ref document: AT

Kind code of ref document: T

Effective date: 20131015

Ref country code: CH

Ref legal event code: PUEA

Owner name: IMCLONE LLC, US

Free format text: FORMER OWNER: UNIVERSITY OF WASHINGTON, US

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20131024

Ref country code: DK

Ref legal event code: T3

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: IMCLONE LLC

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006038813

Country of ref document: DE

Effective date: 20131205

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20131209

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2435727

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20131223

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20130402358

Country of ref document: GR

Effective date: 20140102

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E008869

Country of ref document: EE

Effective date: 20140107

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1135917

Country of ref document: HK

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 16096

Country of ref document: SK

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140710

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006038813

Country of ref document: DE

Effective date: 20140710

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E020600

Country of ref document: HU

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161111

Spc suppl protection certif: 17C0001

Filing date: 20170405

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: LARTRUVO-OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161111

Spc suppl protection certif: 17C0001

Filing date: 20170405

REG Reference to a national code

Ref country code: IT

Ref legal event code: SPCF

Ref document number: 502013902219481

Country of ref document: IT

Free format text: PRODUCT NAME: OLARATUMAB(LARTRUVO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1143/001, 20161111

Spc suppl protection certif: 132017000040358

Ref country code: FI

Ref legal event code: SPCF

Spc suppl protection certif: C20170018

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161109

Spc suppl protection certif: 300869

Filing date: 20170414

Expiry date: 20260618

Extension date: 20310618

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFF

Free format text: PRODUCT NAME: OLARATUMAB (LARTRUVO ); REGISTERED: UK EU/1/16/1143 20161111

Spc suppl protection certif: SPC/GB17/027

Filing date: 20170331

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OLARATUMAB; REG. NO/DATE: EU/1/16/1143 20161111

Spc suppl protection certif: 1790015-0

REG Reference to a national code

Ref country code: IE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: LARTRUVO-OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161109

Spc suppl protection certif: 2017/014

Filing date: 20170411

REG Reference to a national code

Ref country code: LT

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OLARATUMABAS; REGISTRATION NO/DATE: EU/1/16/1143 20161109

Spc suppl protection certif: PA2017011

Filing date: 20170418

Expiry date: 20260619

REG Reference to a national code

Ref country code: EE

Ref legal event code: AA1Y

Ref document number: E008869

Country of ref document: EE

Free format text: PRODUCT NAME: OLARATUMAB;REG NO/DATE: EU/1/16/1143 11.11.2016

Spc suppl protection certif: C20170011

Filing date: 20170410

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R065

Ref document number: 602006038813

Country of ref document: DE

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161109

Spc suppl protection certif: 122017000016

Filing date: 20170405

Expiry date: 20260620

Extension date: 20310619

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161111

Spc suppl protection certif: 300869

Filing date: 20170414

Expiry date: 20260618

Extension date: 20310618

Effective date: 20170524

REG Reference to a national code

Ref country code: HU

Ref legal event code: AA1S

Ref document number: E020600

Country of ref document: HU

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161111

Spc suppl protection certif: S1700015

Filing date: 20170418

REG Reference to a national code

Ref country code: SK

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161111

Spc suppl protection certif: 50005-2017

Filing date: 20170413

REG Reference to a national code

Ref country code: IT

Ref legal event code: SPCG

Ref document number: 502013902219481

Country of ref document: IT

Free format text: PRODUCT NAME: OLARATUMAB(LARTRUVO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1143/001, 20161111

Spc suppl protection certif: 132017000040358

Extension date: 20310619

Ref country code: LU

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OLARATUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (LARTRUVO); AUTHORISATION NUMBER AND DATE: EU/1/16/1143 20161111

Spc suppl protection certif: LUC00012

Filing date: 20170405

Expiry date: 20260619

Extension date: 20310619

Effective date: 20170619

Ref country code: LU

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OLARATUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (LARTRUVO); AUTHORISATION NUMBER AND DATE: EU/1/16/1143 20161111

Spc suppl protection certif: LUC00012

Filing date: 20170405

Expiry date: 20260619

Extension date: 20310619

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG1Y

Ref document number: E008869

Country of ref document: EE

Free format text: PRODUCT NAME: OLARATUMAB;REG NO/DATE: EU/1/16/1143 11.11.2016

Spc suppl protection certif: C20170011 00211

Filing date: 20170410

Extension date: 20310619

REG Reference to a national code

Ref country code: HU

Ref legal event code: FG4S

Ref document number: E020600

Country of ref document: HU

Spc suppl protection certif: S1700015

Filing date: 20170418

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFF

Free format text: PRODUCT NAME: OLARATUMAB; REG. NO/DATE: EU/1/16/1143/001 20161111

Spc suppl protection certif: CA 2017 00015

Filing date: 20170407

Expiry date: 20260619

Extension date: 20310619

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCG

Ref document number: 635268

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 (MITTEILUNG) 20161111

Spc suppl protection certif: 15/2017

Filing date: 20170412

Expiry date: 20260619

Extension date: 20310619

Effective date: 20171115

Ref country code: AT

Ref legal event code: SPCF

Ref document number: 635268

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 (MITTEILUNG) 20161111

Spc suppl protection certif: 15/2017

Filing date: 20170412

Expiry date: 20260619

Extension date: 20310619

Effective date: 20171115

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: SWISSMEDIC 66352 26.09.2017

Filing date: 20180126

Ref country code: CH

Ref legal event code: PUE

Owner name: ELI LILLY AND COMPANY, US

Free format text: FORMER OWNER: IMCLONE LLC, US

REG Reference to a national code

Ref country code: LT

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OLARATUMABAS; REGISTRATION NO/DATE: EU/1/16/1143 20161109

Spc suppl protection certif: PA2017011,C2100614

Filing date: 20170418

Expiry date: 20260619

Extension date: 20310619

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: CT

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161111

Spc suppl protection certif: 17C0001

Filing date: 20170405

Extension date: 20310618

REG Reference to a national code

Ref country code: FR

Ref legal event code: AV

Effective date: 20180528

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OLARATUMAB; REG. NO/DATE: EU/1/16/1143 20161111

Spc suppl protection certif: 1790015-0

Expiry date: 20260620

Extension date: 20310619

REG Reference to a national code

Ref country code: IE

Ref legal event code: SPCG

Free format text: PRODUCT NAME: LARTRUVO-OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161109

Spc suppl protection certif: 2017/014

Extension date: 20310618

Effective date: 20180905

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFG

Free format text: PRODUCT NAME: OLARATUMAB; REG. NO/DATE: EU/1/16/1143/001 20161111

Spc suppl protection certif: CR 2017 00015

Filing date: 20170407

Expiry date: 20260619

Extension date: 20310619

REG Reference to a national code

Ref country code: DE

Ref legal event code: R067

Ref document number: 602006038813

Country of ref document: DE

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161109

Spc suppl protection certif: 122017000016

Filing date: 20170405

Expiry date: 20260620

Extension date: 20310619

REG Reference to a national code

Ref country code: DE

Ref legal event code: R069

Ref document number: 602006038813

Country of ref document: DE

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161109

Spc suppl protection certif: 122017000016

Filing date: 20170405

Expiry date: 20260620

Extension date: 20310619

REG Reference to a national code

Ref country code: SK

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161111

Spc suppl protection certif: 311 50005-2017

Filing date: 20170413

Extension date: 20310620

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66352 26.09.2017

Spc suppl protection certif: C02100614/01

Filing date: 20180126

Extension date: 20310618

REG Reference to a national code

Ref country code: RO

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OLARATUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/16/1143; DATE OF NATIONAL AUTHORISATION: 20161109; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1143; DATE OF FIRST AUTHORISATION IN EEA: 20161109

Spc suppl protection certif: C 2017 013

Extension date: 20310619

Effective date: 20201230

REG Reference to a national code

Ref country code: FI

Ref legal event code: SPCG

Spc suppl protection certif: 620

Extension date: 20310619

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFG

Free format text: PRODUCT NAME: OLARATUMAB, A HUMAN IGG1 MONOCLONAL ANTIBODY; REGISTERED: UK EU/1/16/1143 20161111

Spc suppl protection certif: SPC/GB17/027

Filing date: 20170331

Extension date: 20310618

Effective date: 20210928

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: IMCLONE LLC; US

Effective date: 20230510

REG Reference to a national code

Ref country code: EE

Ref legal event code: HC1A

Ref document number: E008869

Country of ref document: EE

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCN

Spc suppl protection certif: C02100614/01

Representative=s name: E. BLUM AND CO. AG, CH

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250520

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20250526

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20250520

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250521

Year of fee payment: 20

Ref country code: DE

Payment date: 20250520

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250520

Year of fee payment: 20

Ref country code: DK

Payment date: 20250520

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20250520

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20250612

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20250523

Year of fee payment: 20

Ref country code: IT

Payment date: 20250520

Year of fee payment: 20

Ref country code: BE

Payment date: 20250520

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20250520

Year of fee payment: 20

Ref country code: PT

Payment date: 20250521

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: EE

Payment date: 20250605

Year of fee payment: 20

Ref country code: HU

Payment date: 20250613

Year of fee payment: 20

Ref country code: FR

Payment date: 20250520

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20250527

Year of fee payment: 20

Ref country code: GR

Payment date: 20250522

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20250616

Year of fee payment: 20

Ref country code: AT

Payment date: 20250522

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20250526

Year of fee payment: 20

Ref country code: SK

Payment date: 20250526

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20250529

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250522

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20250527

Year of fee payment: 20

Ref country code: SE

Payment date: 20250520

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250701

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250701

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20250522

Year of fee payment: 20